Streetbeat News

Products Services

VALN

Valneva SE has submitted a label extension application to the U.S. FDA for its chikungunya vaccine, IXCHIQ®, to include adolescents and two-year antibody persistence data.

Portfolio Pulse from

November 26, 2024 | 5:00 pm

DKS

Dick's Sporting Goods reported better-than-expected third-quarter 2024 earnings, driven by strategic initiatives, strong execution, and an omnichannel approach, despite macroeconomic challenges.

Portfolio Pulse from

November 26, 2024 | 5:00 pm

GSK

The FDA has accepted GSK's Biologics License Application (BLA) for Blenrep combinations aimed at treating relapsed/refractory multiple myeloma, with a decision expected by July 23, 2025.

Portfolio Pulse from

November 26, 2024 | 4:45 pm

BA

Boeing has secured a $1.7 billion contract to deliver P-8A Poseidon aircraft, which are used for anti-submarine warfare, intelligence, surveillance, and reconnaissance.

Portfolio Pulse from

November 26, 2024 | 4:45 pm

NTLA

Intellia Therapeutics' genome-editing therapy, nex-z, received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. This designation is likely to accelerate the development and review process of the therapy.

Portfolio Pulse from

November 26, 2024 | 4:45 pm

TOL

Toll Brothers, Inc. (NYSE:TOL) announced a new luxury home community, Toll Brothers at August Park, in Spring Hill, Tennessee. Construction begins in January, with sales starting in spring 2025.

Portfolio Pulse from

November 26, 2024 | 4:45 pm

BMBOY

Grupo Bimbo, a large-cap bakery company, is showing potential despite a 30% drop in one-year performance and recent 52-week lows. The company has strong revenue growth in Mexico with a 22% profit margin, driven by smart pricing and successful product launches. Global expansion, particularly in Europe, Asia, and Africa, through organic growth and strategic acquisitions, is boosting profit margins.

Portfolio Pulse from

November 26, 2024 | 4:30 pm

AMGN

Amgen Inc's shares fell 11.6% to a year's low despite successful results from a Phase II trial of its weight-loss drug, MariTide, which showed significant weight loss in participants.

Portfolio Pulse from

November 26, 2024 | 4:30 pm

MRKR

Marker Therapeutics, Inc. (Nasdaq: MRKR) will present at the Citizens JMP Hematology and Oncology Summit on December 2, 2024. The company focuses on developing T cell-based immunotherapies for cancer treatment.

Portfolio Pulse from

November 26, 2024 | 4:15 pm